{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:42:58Z","timestamp":1790109778598,"version":"4.0.1"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1723","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved suzetrigine (Journavx \u2013 Vertex), a selective sodium channel blocker, for oral treatment of moderate to severe acute pain in adults. Suzetrigine is the first sodium channel blocker to be approved in the US for this indication and the first oral nonopioid drug to be approved for treatment of pain in over 25 years.<\/jats:p>","DOI":"10.58347\/tml.2025.1723a","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T21:11:53Z","timestamp":1740690713000},"page":"33-35","source":"Crossref","is-referenced-by-count":10,"title":["Suzetrigine (Journavx) \u2014 A Sodium Channel Blocker for Acute Pain"],"prefix":"10.58347","volume":"67","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"37151","published-online":{"date-parts":[[2025,3,3]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T21:11:54Z","timestamp":1740690714000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1723a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":0,"journal-issue":{"issue":"1723","published-online":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2025.1723a","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]}}}